StoneX Group Inc. Has $4.07 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

StoneX Group Inc. reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 6.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 12,624 shares of the medical research company’s stock after selling 914 shares during the period. StoneX Group Inc.’s holdings in Amgen were worth $4,068,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. Capital Performance Advisors LLP bought a new position in Amgen in the 3rd quarter valued at about $25,000. Hershey Financial Advisers LLC acquired a new position in shares of Amgen in the second quarter valued at approximately $30,000. nVerses Capital LLC bought a new position in shares of Amgen during the second quarter worth approximately $31,000. Bbjs Financial Advisors LLC acquired a new stake in Amgen during the 2nd quarter worth approximately $33,000. Finally, Matrix Trust Co bought a new stake in Amgen in the 3rd quarter valued at $36,000. 76.50% of the stock is owned by institutional investors.

Amgen Stock Up 1.6 %

Shares of AMGN opened at $294.53 on Friday. The stock’s 50-day moving average price is $316.52 and its two-hundred day moving average price is $318.11. Amgen Inc. has a 12 month low of $260.68 and a 12 month high of $346.85. The company has a market capitalization of $158.32 billion, a PE ratio of 37.71, a PEG ratio of 2.59 and a beta of 0.60. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The company had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm’s quarterly revenue was up 23.2% on a year-over-year basis. During the same period in the previous year, the firm earned $4.96 earnings per share. On average, analysts anticipate that Amgen Inc. will post 19.52 EPS for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be given a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a dividend yield of 3.06%. The ex-dividend date is Monday, November 18th. Amgen’s dividend payout ratio (DPR) is presently 115.24%.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $305.00 target price (down previously from $310.00) on shares of Amgen in a report on Wednesday, August 7th. Robert W. Baird reiterated an “underperform” rating and issued a $215.00 price objective on shares of Amgen in a research note on Wednesday, September 25th. Wells Fargo & Company cut Amgen from an “overweight” rating to an “equal weight” rating and lifted their price objective for the company from $320.00 to $335.00 in a report on Wednesday, August 7th. Dbs Bank upgraded Amgen to a “strong-buy” rating in a research report on Monday, September 16th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $405.00 price objective on shares of Amgen in a research report on Tuesday, October 22nd. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Amgen currently has a consensus rating of “Moderate Buy” and a consensus target price of $333.57.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.